Ascletis Pharma Inc. (HKG:1672)
Hong Kong
· Delayed Price · Currency is HKD 9.72
-0.16 (-1.62%)
Jun 26, 2026, 4:08 PM HKT
Ascletis Pharma Employees
Ascletis Pharma had 202 employees as of December 31, 2025. The number of employees decreased by 29 or -12.55% compared to the previous year.
Employees
202
Change (1Y)
-29
Growth (1Y)
-12.55%
Revenue / Employee
11.17K HKD
Profits / Employee
-1.98M HKD
Market Cap
10.32B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 767 |
| HBM Holdings | 272 |
| Everest Medicines | 812 |
| CARsgen Therapeutics Holdings | 355 |
| Suzhou Ribo Life Science | 407 |
| Duality Biotherapeutics | 231 |
Ascletis Pharma News
- 5 days ago - Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity - PRNewsWire
- 20 days ago - Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39 - PRNewsWire
- 7 weeks ago - Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) - PRNewsWire
- 2 months ago - Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions - PRNewsWire
- 2 months ago - Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes - PRNewsWire
- 2 months ago - Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development - PRNewsWire
- 3 months ago - Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity - PRNewsWire
- 4 months ago - Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development - PRNewsWire